Research & Publications
Individuals with HIV, even after effective control of HIV replication, remain at higher risk for some non-AIDS related clinical conditions, including cardiovascular disease, metabolic disorders, and certain malignancies. Our research focuses on understanding those aspects of the immune system that remain impaired despite effective treatment of HIV infection. In addition, we hope to elucidate mechanisms of persistent immunologic aberrancies are associated with clinical disease, including the role of dysregulation of immunometabolism in the setting of HIV infection.
Our laboratory is specifically focused on understanding the pathogenesis, incidence, presentation, and prognosis of cancers in the setting of HIV infection. Individuals with HIV remain at risk for particular malignancies, despite effective control of HIV replication. We will be studying biomarkers that will allow for early diagnosis of patients at increased risk, as well as focusing on the pathologic, molecular, and genetic differences of these cancers in HIV infected individuals compared to individuals without HIV infection, including studies of the tumor microenvironment.
Specialized Terms: HIV and aging; Immune dysfunction in setting of HIV infection
Extensive Research Description
- Evaluation of different T cell phenotypes/function across different ages of HIV-infected indivdiuals on antiretroviral therapy, compared with HIV-uninfected individuals
- Impact of T cell aberrancies on incidence of cancer in the setting of chronic viral infection
- Evaluating immunologic parameters of individuals with cancer diagnoses in setting of HIV infection
Head and Neck Neoplasms; HIV; Immune System; Lymphoma; T-Lymphocytes; Thoracic Neoplasms; Immunocompromised Host; Hematologic Neoplasms; Infectious Disease Medicine; Immune Evasion; Immune Reconstitution
- 437 Safety and efficacy of immune checkpoint inhibitors (ICI) in patients living with HIV (PLWH) and metastatic non-small cell lung cancer (NSCLC): a matched cohort study from the international CATCH-IT consortiumZarif T, Nassar A, Adib E, Fitzgerald B, Huang J, Mouhieddine T, Nonato T, McKay R, Li M, Mittra A, Owen D, Lorentsen M, Dittus C, Dizman N, Emu B, Falohun A, Abdel-Wahab N, Bankapur A, Reed A, Dobbs R, Kim C, Arora A, Shah N, El-Am E, Kozaily E, Abdallah W, Al-Hader A, Ghazal B, Saeed A, Drolen C, Lechner M, Espinar J, Nebhan C, Johnson D, Haykal T, Morse M, Cortellini A, Pinato D, Pria A, Bower M, Hall E, Bakalov V, Bahary N, Rajkumar A, Mangla A, Shah V, Singh P, Nana F, Lia N, Dima D, Funchain P, Saleem R, Woodford R, Long AO G, Menzies A, Genova C, Barletta G, Puri S, Florou V, Idossa D, Queirolo P, Lamberti G, Addeo A, Bersanelli M, Freeman D, Xie W, Ramaswami R, Marron T, Choueiri T, Lurain K, Baden L, Sonpavde G, Naqash A. 437 Safety and efficacy of immune checkpoint inhibitors (ICI) in patients living with HIV (PLWH) and metastatic non-small cell lung cancer (NSCLC): a matched cohort study from the international CATCH-IT consortium 2022, a457-a458. DOI: 10.1136/jitc-2022-sitc2022.0437.
- Impact of HIV infection on clinical outcomes among people diagnosed with head and neck cancer.Salahuddin S, Cohen O, Wu M, Irizarry J, Vega T, Gan G, Deng Y, Isaeva N, Schalper K, Mehra S, Yarbrough W, Emu B. Impact of HIV infection on clinical outcomes among people diagnosed with head and neck cancer. Journal Of Clinical Oncology 2022, 40: e18080-e18080. DOI: 10.1200/jco.2022.40.16_suppl.e18080.
- Abstract 418: Lower survival among HIV-infected head and neck cancer patientsSalahuddin S, Wu M, Irizarry J, Vega T, Isaeva N, Schalper K, Yarbrough W, Emu B. Abstract 418: Lower survival among HIV-infected head and neck cancer patients 2021, 418-418. DOI: 10.1158/1538-7445.am2021-418.
- 661. Ibalizumab Efficacy and Safety Through 48 Weeks of Treatment: Results of an Expanded Access Protocol (TMB-311)Emu B, DeJesus E, Berhe M, Leider J, Creticos C, Weinheimer S, Cohen Z. 661. Ibalizumab Efficacy and Safety Through 48 Weeks of Treatment: Results of an Expanded Access Protocol (TMB-311) Open Forum Infectious Diseases 2019, 6: s303-s303. PMCID: PMC6811265, DOI: 10.1093/ofid/ofz360.729.
- P1.04-23 Characterizing the Tumor Immune Microenvironment of Non-Small Cell Lung Carcinoma in People Living with HIV Using Imaging Mass CytometryYusuf R, Villarroel-Espindola F, Schalper K, Emu B. P1.04-23 Characterizing the Tumor Immune Microenvironment of Non-Small Cell Lung Carcinoma in People Living with HIV Using Imaging Mass Cytometry Journal Of Thoracic Oncology 2019, 14: s448. DOI: 10.1016/j.jtho.2019.08.926.
- Phase I study of pembrolizumab in people with HIV and cancer.Uldrick T, Goncalves P, Abdul Hay M, Claeys A, Emu B, Ernstoff M, Fong L, Kaiser J, Kohrt H, Lacroix A, Lee S, Lundgren L, Lurain K, Parsons C, Peeramsetti S, Ramaswami R, Sharon E, Wang C, Yarchoan R, Cheever M. Phase I study of pembrolizumab in people with HIV and cancer. Journal Of Clinical Oncology 2019, 37: 2500-2500. DOI: 10.1200/jco.2019.37.15_suppl.2500.
- OP8.3 Interim safety analysis of cancer immunotherapy trials Network – 12 (CITN-12): a Phase 1 study of pembrolizumab in patients with HIV and cancerUldrick T, Cheever M, Gonçalves P, Fling S, Aleman K, Emu B, Ernstoff M, Gorelick R, Kaiser J, Kohrt H, Lacroix A, Lindsley M, Lundgren L, Lurain K, Maldarelli F, Parsons C, Sharon E, Widell A, Yarchoan R. OP8.3 Interim safety analysis of cancer immunotherapy trials Network – 12 (CITN-12): a Phase 1 study of pembrolizumab in patients with HIV and cancer Journal Of Virus Eradication 2017, 3: 55-56. DOI: 10.1016/s2055-6640(20)30567-7.
- Forty-eight-Week Safety and Efficacy On-Treatment Analysis of Ibalizumab in Patients with Multi-Drug Resistant HIV-1Emu B, Fessel W, Schrader S, Kumar P, Richmond G, Win S, Weinheimer S, Marsolais C, Lewis S. Forty-eight-Week Safety and Efficacy On-Treatment Analysis of Ibalizumab in Patients with Multi-Drug Resistant HIV-1 Open Forum Infectious Diseases 2017, 4: s38-s39. PMCID: PMC5632088, DOI: 10.1093/ofid/ofx162.093.
- Is opioid use associated with T cell dysfunction?Armah K, Edelman E, Cheng D, Doyle M, Coleman S, Bridden C, Gnatienko N, Lioznov D, Blokhina E, Emu B, Freiberg M, Krupitsky E, Samet J. Is opioid use associated with T cell dysfunction? Drug And Alcohol Dependence 2015, 156: e9. DOI: 10.1016/j.drugalcdep.2015.07.943.
- Potential inflammatory consequences in HIV controllersHunt P, Hsue P, Sinclair E, Landay A, Martinson J, Hatano H, Emu B, Norris P, Busch M, Martin J, Brooks C, McCune J, Deeks S. Potential inflammatory consequences in HIV controllers Retrovirology 2010, 7: i28. PMCID: PMC3315933, DOI: 10.1186/1742-4690-7-s1-i28.